Abbreviations: CMAP ϭ compound muscle action potential; CMT ϭ Charcot-Marie-Tooth disease; FDS ϭ functional disability scale; GNDS ϭ global NDS; MNCV ϭ motor nerve conduction velocity; MNDS ϭ motor NDS; NDS ϭ neurological disability score; P 0 ϭ peripheral myelin P 0 protein; PMP22 ϭ peripheral myelin protein 22
Summary

Introduction
The syndrome of peroneal muscular atrophy was first disease duration, may be important for understanding the physiopathology. described more than a century ago by Charcot and Marie in France (1886) and Tooth in England (1886) . We are,
We report here the clinical and electrophysiological features of a large and genetically homogeneous group of CMT1 however, indebted to Dyck and Lambert (1968) for the first comprehensive classification of the syndrome. They patients with 17p11.2 duplication, including a study of the disease-severity factors and intrafamilial variations within distinguished different types according to clinical, genetic, electrophysiological and histological characteristics. The the phenotype. heterogeneity of the syndrome was therefore clearly established. The absence of peroneal atrophy in some affected members of a family was observed and led Dyck to prefer
Patients and methods
the term hereditary motor and sensory neuropathy to the We studied 119 patients with proven 17p11.2 duplication. more restrictive term of peroneal muscular atrophy or All were investigated in the same institution in Paris and Charcot-Marie-Tooth syndrome (CMT). A classification examined by the same neurologist according to a defined based on seven types was then proposed (Dyck, 1975) and clinical and electrophysiological protocol. was adopted by most neurologists and geneticists. Hereditary
French CMT network criteria were used for diagnostic motor and sensory neuropathy Type I corresponded to the purposes; in the CMT1 type, index cases had to present hypertrophic and more frequent form of the disease, (i) slowly progressive, bilateral and symmetrical distal characterized by onion bulb formation observed on nerve weakness and wasting in limbs with areflexia (at least of biopsy specimens. Hereditary motor and sensory neuropathy ankle jerks) and distal sensory loss in lower extremities, and Type II was the neuronal form. Electrophysiological studies (ii) a median nerve MNCV of ഛ30 m/s. At-risk relatives confirmed the discrimination between Types I and II according were considered affected if the MNCV was ഛ30 m/s or to the values of median motor nerve conduction velocity ഛ40 m/s on two nerves, i.e. both median nerves or the ulnar (MNCV) (Harding and Thomas, 1980a, b; Bouche et al., and median nerves, with all or some CMT clinical features 1983). The first genetic confirmation of this heterogeneity (at least ankle jerk areflexia or pes cavus). appeared in the early 1980s. Some families classified as hereditary motor and sensory neuropathy Type I were found to be linked to the Duffy locus on chromosome 1 (Bird et al., Clinical assessment 1982). Later, a duplication of a region on chromosome 17
Age at onset was determined by questioning the patients containing the peripheral myelin protein 22 (PMP22) gene about the age of the first symptoms such as cramps, difficulty was found in numerous Type I families (Vance et al., 1989;  in running, jumping, climbing stairs and walking. Raeymaekers et al., 1989 Raeymaekers et al., , 1991 Middleton-Price et al., 1990;  A personal neurological disability score (NDS) was derived Lupski et al., 1991; Brice et al., 1992; Matsunami et al., from neurological examination findings and determined as 1992; Patel et al., 1992; Timmerman et al., 1992) . More follows: (i) muscle weakness and muscle wasting, scored recently, other loci have been found and a new classification separately where 0 ϭ normal, 2 ϭ in either the upper or has had to be proposed (Harding, 1995) . The CMT eponym lower limbs, 4 ϭ in both; (ii) upper limb tendon reflexes has now been adopted. CMT1A corresponds to patients with where 0 ϭ normal, 1 ϭ absent; (iii) lower limb tendon 17p11.2 duplication or PMP22 point-mutation, CMT1B to reflexes where 0 ϭ normal, 1 ϭ either knee jerk or ankle patients with peripheral myelin P 0 protein (P 0 ) mutations on jerk absent, 2 ϭ both absent; (iv) sensory loss with painchromosome 1 and CMT1C to patients where a locus has touch and proprioception scored separately where 0 ϭ normal, yet to be discovered (Chance et al., 1990) . CMT2 patients 1 ϭ in either the upper or lower limbs, 2 ϭ in both. are those with the neuronal form. Other CMT types have sex-
The motor neurological disability score (MNDS), including linked (CMTX) or autosomal recessive (CMT4) inheritance muscle weakness and muscle wasting, was assessed on a (Gabreëls-Festen et al., 1993; Ionasescu, 1995) . The CMT1A scale from 0 to 8. The global neurological disability score type appears to be by far the most frequent and accounts for (GNDS), including the MNDS, sensory loss and areflexia, 60-70% of CMT1 cases (Ionasescu, 1995) .
was assessed on a scale from 0 to 15. CMT1A patients with the 17p11.2 duplication have the To determine disease severity in terms of ability to walk same genetic defect but present a wide range of clinical and run, each patient was assessed according to a nine-point disability. A knowledge of the relationships between the functional disability scale (FDS) from 0 to 8 as follows: phenotypic variations and other parameters, such as electro-0 ϭ normal; 1 ϭ normal, but with cramps and fatigability; 2 ϭ inability to run; 3 ϭ walking difficult but still possible physiological findings, age, gender, parental transmission and unaided; 4 ϭ able to walk with a cane; 5 ϭ able to walk considered significant with correlation coefficient r ജ 0.4 and P ഛ 0.001. with crutches; 6 ϭ able to walk with a walker; 7 ϭ wheelchair bound; 8 ϭ bedridden.
In addition, all individuals were examined for the presence of foot deformities, scoliosis, nerve hypertrophy and Results associated signs (tremor, ataxia, pyramidal signs, deafness,
Molecular diagnosis
optic nerve atrophy and dementia).
On the basis of clinical and electrophysiological criteria, 93 CMT1 families were investigated and tested for the 17p11.2 duplication. Where no duplication was detected, P 0 mutations Electrophysiological study were sought. Nerve conduction studies were performed with surface Fifty-five families presented the 17p11.2 duplication and stimulating and recording electrodes. Distal motor latency, were thus classified as CMT1A; five families had P 0 point MNCV and distal compound muscle action potential (CMAP) mutations. For the remaining 33 families the genetic defect were recorded from the median nerve in all patients; ulnar could not be characterized. and peroneal nerves were studied in most of the index cases.
Clinical and electrophysiological examinations were A terminal latency index was calculated for the median nerve performed in 196 individuals belonging to the 55 CMT1A as follows:
families. Of the 141 at-risk relatives, 77 were found to be Terminal latency index ϭ terminal distance (mm)/ affected; 64 were normal on clinical and electrophysiological [MNCV (m/s)ϫdistal motor latency (ms)] examination and did not carry the duplication. The 17p11.2 duplication was detected in 132 individuals; 13 cases The terminal distance was fixed at 60 mm. Terminal (belonging to five families) were excluded from the study latency index values were compared with those of 200 because of incomplete clinical and/or electrophysiological normal controls.
data. Sensory-nerve action potentials were recorded from median
The remaining 119 patients with the 17p11.2 duplication and sural nerves in all index cases and, in some instances, therefore formed the basis of the present study. in relatives.
Electromyography of the tibialis anterior and the first dorsalis interosseous muscles was performed with a concentric needle electrode in index patients.
Clinical findings
The electrophysiological examination protocol was
General findings
simplified for at-risk relatives if the examination was Fifty-four males and 65 females were studied. Mean age carried out at home or in children (and included at least an at examination was 40.2 Ϯ 18.6 years (mean Ϯ SD; range MNCV study on the median nerve).
2-81 years). Non-symptomatic at-risk relatives (n ϭ 32, i.e. 27%) were systematically screened for CMT1A. Mean age at onset in symptomatic individuals was 19.4 Ϯ 17.4 years
Molecular study
(range 2-76 years). The 17p11.2 duplication was detected by gene dosage using
The disease was transmitted from an affected father in 51 RFLP (restriction fragment length polymorphism) probes cases and from an affected mother in 43 cases. Parental localized in the CMT1/hereditary neuropathy with pressure transmission was unknown in the remaining cases. palsies monomer. The genomic probes EW 401 (D17S61) and VAW412R3 (D17S125) each detect two MspI alleles 10.5 and 5.4 kb, and 5.5 and 4.4 kb long, respectively, and VAW409R3a (D17S122) detects three MspI alleles of 2.8,
Neurological examination findings
Motor and sensory loss predominated in the lower limbs in the 2.7 and 1.9 kb. Patient DNA (5 mg), digested with MspI, was electrophoresed on 0.8% agarose gels, transferred to majority of patients, foot deformities were almost invariably present and one-third of patients had kyphoscoliosis. The Hybond Nϩ membrane (Amersham, UK) and hybridized with random-primed 32 P-labelled probes, after preannealing most frequently observed associated signs were postural hand tremor (5% of patients; n ϭ 6) and hypoacousia (5% of with placental DNA (2 mg/l). Gene dosage was performed by visual inspection.
patients; n ϭ 6). No patient had pyramidal or cerebellar signs (Table 1) . GNDS findings are shown in Fig. 1A . One-third of the patients had the maximum score (GNDS ϭ 15) with motor and
Statistical analysis
Percentages and means were compared using the χ 2 test and sensory loss and areflexia of both the upper and lower limbs. Twenty patients (17%) had few signs (GNDS ϭ 1-5); in Student's t test, respectively; differences were considered significant for P ഛ 0.05. Correlation studies were performed most of them the neuropathy was asymtomatic and diagnosed during the familial investigation. No affected individual had using simple regression analysis; the correlation was completely normal clinical findings, there was at least pes unit potential recruitment was reduced in all cases for the first dorsalis interosseous muscle and in 92% of cases for cavus and/or ankle jerk areflexia.
Functional disability was mild or absent (FDS ϭ 0 or 1) the tibialis anterior muscle. In 6% of cases no motor unit potential recruitment was elicited in the tibialis anterior in 41 patients (35%); 72 patients (61%) were at stage 2 or 3, with difficulty in walking or running but were still muscle. autonomous; one patient was wheelchair bound but did not differ from the patients with a high FDS (stage ജ3) in terms of age at onset or median nerve MNCV (Fig. 1B) .
Correlation study Neurological deficit, FDS and electrophysiological findings by gender and Electrophysiological findings parental transmission
All patients had marked slowing of motor nerve conduction No significant difference was found in the GNDS, MNDS, ( Table 2 ). The MNCV could not be measured in four cases FDS, median nerve MNCV and CMAP amplitude, between (4%) for the median nerve and in 24 cases (54%) for the males and females, or between two groups of patients peroneal nerve. There was neither conduction block nor distinguished according to the gender of the affected parent. dispersion of action potentials. The CMAP amplitude was frequently reduced (87% of cases for the median nerve and 93% of cases for the peroneal and ulnar nerves). The median
Neurological deficit, FDS and
nerve MNCV was almost invariably ഛ30 m/s, except in four electrophysiological findings by age at onset, individuals (with 31, 31.5, 32 and 33 m/s) who were at-risk relatives (Fig. 1D ). Median nerve terminal latency index age at examination, and disease duration
The median nerve MNCV was directly related to age at did not differ from 183 normal controls (0.34 Ϯ 0.1 for patients versus 0.34 Ϯ 0.04 for controls).
onset (r ϭ 0.47, P Ͻ 0.001) (Fig. 2 ). Patients were subdivided into two groups according to their age at onset: an early Sensory action potentials were abnormal in all tested cases. They could not be recorded in 98% of cases for the sural onset group (77 patients; age at onset ഛ20 years) and a late onset group (41 patients; age ജ21 years) ( Table 3 ). The age nerve and in 85% of cases for the median nerve.
Fibrillation potentials were rarely observed (15%). Motor of 20 years was chosen as a dividing line between the two groups for two reasons: it was close to the mean age at over an average evolution of 2 years, and from stage 2 to stage 3 and above over an average of 7 years. However, onset (19.4 years) and it corresponds to the upper limit of growing age. Functional disability was significantly higher early onset patients remained pauci-symptomatic (FDS ϭ 1) for a longer time than late onset patients. In addition, age at in early onset patients, whose mean age at examination was significantly lower than that of the late onset group (P Ͻ examination in each FDS group was markedly lower in early onset than in late onset patients. Early onset patients, 0.01). The disease duration was significantly longer, and the median nerve MNCV significantly more reduced, in early therefore, reached high functional disability significantly earlier. onset patients (P Ͻ 0.01). No difference was found in the GNDS and median nerve CMAP between the two groups of No correlation was found between either disease duration or age at examination and median nerve MNCV or CMAP patients. The disease duration was compared between early and late onset patients for three different functional disability amplitude (Fig. 2) . groups ( 
Clinical and electrophysiological variations within the same family
Eight families with four to eight affected members were Table 2 Motor nerve conduction findings in 119 CMT1A studied (Fig. 3) . Median nerve MNCV varied considerpatients with 17p11.2 duplication ably within families (lowest value 9.5 m/s, highest value with those of 10 patients belonging to five families with P 0 point mutation reported previously by Rouger et al. between the severity of the disorder on the one hand and clinical and electrophysiological data on the other. (1996) . The GNDS and MNDS were significantly higher in CMT1A patients. No differences were found in FDS or MNCV of median ulnar and peroneal nerves. However, distal motor latencies were significantly greater and CMAP
Clinical and electrophysiological characteristics
In our patients with CMT1A and in previous large series of amplitudes significantly lower in CMT1A patients. No differences were found in sensory action potentials or CMT1 cases (Dyck 1975; Buchthal and Behse, 1977; Harding and Thomas, 1980a) , onset was in the first decade in 50% electromyography recruitment (Table 6) . of cases and before the age of 20 years in 70% of patients (Fig. 1C) . The age at onset was determined by questioning the patients about their first disabling symptoms; hence, it
Discussion
The present group of CMT1A patients with 17 p11.2 characterized the first functional manifestations rather than the onset of the disorder process itself, which could have duplication is the largest to be reported so far. This genetically homogeneous group underwent a detailed clinical and begun in early childhood or even before. The fact that CMT1 is a slowly progressive disorder could make the time of onset electrophysiological analysis and a study of the relationship imprecise, especially in older patients who may not remember of the disorder in 114 patients. The close correlation in distribution of age at onset between the reported groups of precisely the age at which the first symptoms occurred. In asymptomatic patients, the age at onset cannot be determined.
CMT1 patients would seem to confirm the validity of the method used to determine this parameter. Such problems in timing the onset were emphasized by Harding and Thomas (1980a) . In our study, detailed questions Clinical features were dominated by areflexia and foot deformities (omnipresent), and by muscle weakness and about the patient's age at the time of the first symptoms, such as cramps, difficulty in running, jumping and climbing wasting, which predominated in the lower limbs. Sensory loss, dominated by proprioception loss, was noted in Ͼ75% stairs, allowed us to date as precisely as possible the onset then be distinguished according to the severity of functional disability: asymptomatic patients (FDS ϭ 0 or 1) and symptomatic patients (FDS ജ 2). Symptomatic patients had earlier onset, longer disease duration, a higher NDS and an even slower nerve conduction than asymptomatic patients. Our FDS was reliable for determining disease severity in the lower limbs whether it was related to motor deficit or to ataxia due to proprioception loss, which could be severe in some instances. As reported previously (Berciano et al., 1989; Nicholson, 1991; Kaku et al., 1993a) , MNCV constitutes a reliable tool for screening affected at-risk relatives. Conduction slowing was fully consistent with DNA analysis, even in children and clinically asymptomatic individuals. Eight children were diagnosed before the age of 10 years (range 2-9 years); all of them had an evident CMT1 phenotype with a reduced median nerve MNCV ranging from 10 to 31 m/s. The youngest was a 2-year-old girl with muscle wasting and weakness of the lower limbs, ankle jerk areflexia and a These results confirm the complete electrophysiological penetrance of CMT1A with 17p11.2 duplication. of patients. Associated signs were rare. Neither cerebellar nor pyramidal signs were observed. These data did not differ
The highest value for the median nerve MNCV was 33 m/s, whereas in other series of CMT1A patients with from other large groups of CMT1 patients (Dyck and Lambert, 1968; Harding and Thomas, 1980a; Berciano et al., 1989) 17p11.2 duplication it reached 38 or 42 m/s (Nicholson, 1991; Kaku et al., 1993a) . This difference could be due or the smaller series of CMT1A patients with 17p11.2 duplication (Hoogendijk et al., 1994) . Proximal motor deficit to our electrophysiological criteria, but 35 families with intermediate MNCV (30 to 40 m/s) in the index patient did has rarely been reported and was not observed in our patients, although Hoogendijk et al. (1994) reported proximal paresis not carry the 17p11.2 duplication. The median nerve terminal latency index, which explores in 11% of cases.
Functional disability was judged on a simple scale based the ratio between distal and proximal conduction velocity , did not differ from that in controls. In on the ability to walk and run. Severe disability was rarely observed. Only four individuals (3.4%) needed a cane for addition, neither conduction block nor temporal dispersion of action potentials was observed. These data confirm the walking, and one patient was wheelchair bound. Patients became truly symptomatic with the onset of running uniform slowing of motor nerve conduction between proximal and distal segments. Sensory nerve potentials were abnormal difficulties (FDS ϭ 2), two different groups of patients could in all patients, and were abolished in most cases even though 1980a; Bouche et al., 1983) . In our study of CMT1A patients, the median nerve MNCV was significantly more reduced in patients did not have clinical sensory loss. All previous electrophysiological descriptions of CMT1 have underlined patients with high functional disability. These data appear to confirm those of Hoogendijk et al. (1994) , who found that these characteristics (Buchthal and Behse, 1977; Harding and Thomas, 1980a; Bouche et al., 1983; Ouvrier et al., 1987;  the MNCV was inversely related to neurological disability, though there were differences in the assessment scale used Kaku et al., 1993a, b) .
Clinical and electrophysiological characteristics of our in the two studies; in our study functional disability was determined by the effect of the disorder on the ability to CMT1A patients did not significantly differ from those previously reported in CMT1 patients without molecular walk and run, whereas in previous reports, clinical severity was evaluated using a neurological disability scale derived diagnosis or CMT1A patients with proven 17p11.2 duplication. This could be due to the fact that the duplication from a neurological examination especially designed for this purpose. Our cross-sectional analysis findings and those of in 17p11.2 is the most frequent molecular defect in CMT1. In contrast with the results of Dyck et al. (1989) , we found Hoogendijk et al. (1994) are close to those in a longitudinal study reported by Dyck et al. (1989) of 31 patients (one that the disease is more severe in CMT1A patients than in CMT1B patients. This divergence may be explained by the CMT1B patient with linkage to the Duffy locus; and 30 CMT1 patients without linkage to the Duffy locus), which smaller number of CMT1B patients in our study and the fact that CMT1A patients in the study of Dyck et al. (1989) showed that the severity of conduction-velocity abnormality predicted clinical severity, since it was significantly associated corresponded to patients without linkage to the Duffy locus, and so could include CMT1A and CMT1C patients in the with the NDS and subsets of the NDS. They also found that the CMAP amplitude tended to decrease with age more most recent classification. However, our results demonstrate that CMT1B is not always associated with a severe phenotype.
frequently in the peroneal nerve than in the ulnar and median nerves. We were unable to perform the same cross-sectional analysis with peroneal MNCVs and CMAPs because no response could be elicited in peroneal nerve in 50% of cases,
Correlation study and disease-severity factors
Previous reports underlined phenotype variations in CMT1 making the number of patients in each subgroup (determined by age at onset or FDS) too small for reliable statistical patients and tried to establish a causal relation between electrophysiological characteristics and clinical severity analysis. Killian et al. (1996) reported a longitudinal evaluation of nerve conduction within a single family with (Dyck et al., 1989; Nicholson, 1991; Kaku et al., 1993a; Hoogendijk et al., 1994; Killian et al., 1996) . Few studies 17p11.2 duplication over a period of 22 years. The MNCV did not change significantly whereas functional worsening have tried to find an association between age at onset and severity of the disorder. Harding and Thomas (1980a) was noticed in half of the patients; age at onset was not, however, specified for these patients. The clinical progression considered that age of onset was not a reliable indicator of disease severity. Our study suggests that functional disability of the disorder could be due to other, unknown factors, probably related to the demyelination/remyelination process is related to disease duration. However, disease course is dependent on age at onset. Indeed, patients with onset before rather than to axonal loss, as previously stated by Roy et al. (1989) in a longitudinal study performed in 10 CMT1 patients the age of 20 years remained pauci-symptomatic much longer than late onset patients. This could be due to factors relating which found a decrease in the median nerve CMAP with no significant change in the MNCV or distal motor latency. We to remyelination/regeneration capabilities in younger patients. Indeed, serial biopsy studies reported an increase in the found no difference in median nerve CMAP amplitudes between the three FDS groups and no correlation was found number and size of onion bulb formations with age (Meier et al., 1976; Ouvrier et al., 1987; Gabreëls-Festen et al., between the median nerve CMAP and disease duration or age at examination. As CMT1A is a slowly progressive 1992), but they did not give a description of axonal status. In the late stages (FDS ജ 2), the progression is similar in disorder, a possible regeneration process could explain the absence of a decrease in CMAP amplitude during the course early and late onset groups. However, early onset patients can reach a high FDS stage relatively early, compared with of the disease.
Regardless of age at onset, CMT1A with 17p11.2 late onset patients, since the latter developed the disease after the fourth decade in 46% of cases and the former during the duplication is a progressive disorder, but early onset is highly correlated with a high functional disability and low MNCV. first decade in 70% of cases. The factors that could explain such differences in onset, which exist even among siblings, Age at onset and median nerve MNCV combined could, therefore, be valuable prognostic factors in CMT1A patients. have yet to be determined; in this respect, additional hypothetical genetic mechanisms related to PMP22 expression could prevent the early manifestation of the Intrafamilial variation within the CMT1A disorder in some individuals.
The absence of any correlation between the MNCV and phenotype
The phenotypical expression of the same genetic defect is clinical severity in CMT1 patients was underlined by previous investigators (Dyck and Lambert, 1968 Kaku et al. (1993a) . The pathogenesis of this Genet 1992; 29: 807-12. variation remains unclear. Furthermore, Garcia et al. (1995) reported clinical variation in two pairs of identical twins. 
Conclusions
We conclude that MNCV slowing is a reliable tool in onset is a reliable tool to determine disease severity; the
